

# Unmet Needs in Cholangiocarcinoma

Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary tumours that can arise from the intrahepatic, perihilar or distal parts of the biliary tree.<sup>1</sup> Each anatomical tumour subtype has distinct epidemiology, molecular characteristics, prognosis and strategy for clinical management.<sup>2</sup> Although rare (0.4–1.8 per 100,000 cases across Europe),<sup>3</sup> the incidence of CCA, in particular intrahepatic CCA, is generally increasing worldwide.<sup>1</sup> Diagnosis remains a challenge, due to the asymptomatic nature of the disease in its early stages and its non-specific clinical presentation.<sup>1</sup> As a result, ~70% of patients are diagnosed with advanced disease, which compromises therapeutic options.<sup>1</sup>


During the past decade, improvements in treatment outcomes and survival for patients with CCA have been relatively limited.<sup>1</sup> Patient prognosis remains poor, with a 5-year survival rate of <20%.<sup>4</sup> There is a clear need for novel therapeutic approaches and optimised clinical management, especially for the large proportion of patients diagnosed with advanced disease.<sup>5</sup> The introduction of next-generation sequencing technologies has opened new horizons for a better understanding of the molecular basis of CCA, and for the identification and evaluation of potential new treatments tailored to the molecular characteristics of patients' tumours.<sup>5</sup>

## What is Incyte doing to address unmet needs in CCA?

Here at Incyte, we believe that raising disease awareness is crucial, in order to improve diagnosis and outcomes for patients with CCA.

- We sponsor the Global Cholangiocarcinoma Alliance (GCA), an initiative that aims to increase awareness of CCA globally and establish a united voice through community collaborations.
- We collaborate with The Alan Morement Memorial Fund (AMMF), a registered charity based in the UK which works nationally and internationally and is dedicated to raising awareness, supporting research and providing information on CCA.
- Our CCA disease education website for European healthcare professionals aims to broaden awareness of CCA disease and the importance of comprehensive molecular profiling.

**Discover more at: [www.cholangiocarcinoma-eu.com](http://www.cholangiocarcinoma-eu.com)**



**SOLVE  
ON.**

Date of preparation: September 2020  
BE/OTHR/M/20/0024

© 2020, Incyte Biosciences International Sàrl. All rights reserved

- Incyte-sponsored satellite symposia focusing on CCA took place at both the International Liver Cancer Association (ILCA) Conference and the European Society for Medical Oncology (ESMO) Congress in September 2020.
  - Our ILCA symposium 'Personalised Approaches in Cholangiocarcinoma' explored clinical and genetic heterogeneity in CCA and their potential relevance to disease management. [Watch the full symposium here.](#)
  - Our ESMO symposium 'Patient Centricity in Cholangiocarcinoma: A Multidisciplinary Discussion' critically discussed the importance of multidisciplinary team (MDT) decision-making to optimise patient outcomes. [Watch the full symposium here.](#)
- We are collaborating with an MDT Steering Committee to identify and develop the key materials required to address the educational needs of the MDT members involved in the management of patients with CCA.
- We provide institutional support for articles covering key topics relating to CCA disease, diagnosis, the role of molecular profiling and the available treatment options.
- Our Phase 3 FIGHT-302 trial is currently recruiting to evaluate the efficacy and safety of pemigatinib (an oral inhibitor of fibroblast growth factor receptors 1–3) versus gemcitabine plus cisplatin chemotherapy in first-line treatment of patients with unresectable or metastatic CCA with *FGFR2* rearrangements. [Discover more here.](#)

#### References

1. Banales JM, et al. *Nat Rev Gastroenterol Hepatol*. 2020;17:557–88.
2. Rizvi S, et al. *Nat Rev Clin Oncol*. 2018;15:95–111.
3. Blechaz B. *Gut Liver*. 2017;11:13–26.
4. DeOliveira ML, et al. *Ann Surg*. 2007;245:755–62.
5. Simile MM, et al. *Medicina (Kaunas)*. 2019;55:42.



**SOLVE**  
**ON.**

Date of preparation: September 2020  
BE/OTHR/M/20/0024

© 2020, Incyte Biosciences International Sàrl. All rights reserved